Sophia Dahmani1, Nicholas Kaliss1, John W VanMeter1, David J Moore1, Ronald J Ellis1, Xiong Jiang2. 1. From the Department of Neuroscience (S.D., N.K., X.J.) and Department of Neurology (J.W.V.), Georgetown University Medical Center, Washington, DC; Department of Psychiatry (D.J.M., R.J.E.) and Department of Neurosciences (R.J.E.), University of California, San Diego, La Jolla. 2. From the Department of Neuroscience (S.D., N.K., X.J.) and Department of Neurology (J.W.V.), Georgetown University Medical Center, Washington, DC; Department of Psychiatry (D.J.M., R.J.E.) and Department of Neurosciences (R.J.E.), University of California, San Diego, La Jolla. xiong.jiang@georgetown.edu.
Abstract
OBJECTIVE: A meta-analysis of proton magnetic resonance spectroscopy studies to investigate alterations in brain metabolites in people with HIV (PWH), the relationship between metabolite alterations and combination antiretroviral therapy (cART), and the relationship between metabolite alterations and cognitive impairment. METHODS: The PubMed database was searched for studies published from 1997 to 2020. Twenty-seven studies were identified, which included 1255 PWH and 633 controls. Four metabolites (N-acetyl aspartate [NAA], myo-inositol [mI], choline [Cho], and glutamatergic metabolites [Glx]) from 5 brain regions (basal ganglia [BG], frontal gray and white matter [FGM and FWM], and parietal gray and white matter [PGM and PWM]) were pooled separately using random-effects meta-analysis. RESULTS: During early HIV infection, metabolite alterations were largely limited to the BG, including Cho elevation, a marker of inflammation. cART led to global mI and Cho normalization (i.e., less elevations), but improvement in NAA was negligible. In chronic PWH on cART, there were consistent NAA reductions across brain regions, along with Cho and mI elevations in the FWM and BG, and Glx elevations in the FWM. Cognitive impairment was associated with NAA reduction and to a lesser degree mI elevation. CONCLUSIONS: The BG are the primary region affected during early infection. cART is successful in partially controlling neuroinflammation (global mI and Cho normalization). However, neuronal dysfunction (NAA reductions) and neuroinflammation (mI and Cho elevations) persist and contribute to cognitive impairment in chronic PWH. Novel compounds targeting NAA signal pathways, along with better neuroinflammation control, may help to reduce cognitive impairment in PWH.
OBJECTIVE: A meta-analysis of proton magnetic resonance spectroscopy studies to investigate alterations in brain metabolites in people with HIV (PWH), the relationship between metabolite alterations and combination antiretroviral therapy (cART), and the relationship between metabolite alterations and cognitive impairment. METHODS: The PubMed database was searched for studies published from 1997 to 2020. Twenty-seven studies were identified, which included 1255 PWH and 633 controls. Four metabolites (N-acetyl aspartate [NAA], myo-inositol [mI], choline [Cho], and glutamatergic metabolites [Glx]) from 5 brain regions (basal ganglia [BG], frontal gray and white matter [FGM and FWM], and parietal gray and white matter [PGM and PWM]) were pooled separately using random-effects meta-analysis. RESULTS: During early HIV infection, metabolite alterations were largely limited to the BG, including Cho elevation, a marker of inflammation. cART led to global mI and Cho normalization (i.e., less elevations), but improvement in NAA was negligible. In chronic PWH on cART, there were consistent NAA reductions across brain regions, along with Cho and mI elevations in the FWM and BG, and Glx elevations in the FWM. Cognitive impairment was associated with NAA reduction and to a lesser degree mI elevation. CONCLUSIONS: The BG are the primary region affected during early infection. cART is successful in partially controlling neuroinflammation (global mI and Cho normalization). However, neuronal dysfunction (NAA reductions) and neuroinflammation (mI and Cho elevations) persist and contribute to cognitive impairment in chronic PWH. Novel compounds targeting NAA signal pathways, along with better neuroinflammation control, may help to reduce cognitive impairment in PWH.
Authors: Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich Journal: Neurology Date: 2014-09-26 Impact factor: 9.910
Authors: Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur Journal: Nat Rev Neurol Date: 2016-04-15 Impact factor: 42.937
Authors: Borja Mora-Peris; George Bouliotis; Kulasegaram Ranjababu; Amanda Clarke; Frank A Post; Mark Nelson; Laura Burgess; Juan Tiraboschi; Saye Khoo; Steve Taylor; Deborah Ashby; Alan Winston Journal: AIDS Date: 2018-05-15 Impact factor: 4.177
Authors: Shida Banakar; M Albert Thomas; Audra Deveikis; June Q Y Watzl; Judy Hayes; Margaret A Keller Journal: J Magn Reson Imaging Date: 2008-04 Impact factor: 4.813
Authors: Albert M Anderson; Christine Fennema-Notestine; Anya Umlauf; Michael J Taylor; David B Clifford; Christina M Marra; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Susan Morgello; Igor Grant; Scott L Letendre Journal: J Neurovirol Date: 2015-06-12 Impact factor: 3.739
Authors: Leah H Rubin; Ned Sacktor; Jason Creighton; Yong Du; Christopher J Endres; Martin G Pomper; Jennifer M Coughlin Journal: AIDS Date: 2018-07-31 Impact factor: 4.632
Authors: Xiong Jiang; Sophia Dahmani; Margarita Bronshteyn; Fan Nils Yang; John Paul Ryan; R Craig Gallagher; Srikanth R Damera; Princy N Kumar; David J Moore; Ronald J Ellis; Peter E Turkeltaub Journal: PLoS One Date: 2022-06-03 Impact factor: 3.752